Urodynamic and clinical effects of noninvasive and minimally invasive treatments in elderly men with lower urinary tract symptoms stratified according to the grade of obstruction.
OBJECTIVE
We investigated the symptomatic and urodynamic effects of several noninvasive and minimally invasive treatment modalities to quantify these effects and to compare subjective and objective results within groups with various degrees of obstruction.


METHODS
In a prospective study at one center, 487 patients who completed a full screening program including urodynamic investigation started treatment with watchful waiting, terazosin, transurethral microwave thermotherapy, or laser treatment of the prostate; they were re-evaluated symptomatically and urodynamically after 6 months of therapy. The symptomatic and urodynamic results of 87 patients from another center who underwent transurethral resection of the prostate and who had their second urodynamic evaluation 6 months after surgery were also included.


RESULTS
In patients without bladder outlet obstruction (BOO), improvement in maximum flow and symptom scores with little change in the degree of obstruction was most apparent, whereas a decrease of detrusor pressure at maximum flow was observed mainly in patients with BOO. The urodynamic effect but not the symptomatic effect of treatments depended on the initial grade of BOO. Urodynamic changes were more marked in the minimally invasive treatment groups compared with the noninvasive treatment groups.


CONCLUSIONS
In symptomatic patients with benign prostatic hyperplasia, symptomatic improvement in the short term does not seem to depend on changes in urodynamic parameters. Future well-controlled studies focusing on the durability of symptomatic and urodynamic effects will be needed to illustrate the relative potential of urodynamic and other clinical parameters to predict a favorable response to current and innovative treatments.
Witjes
W P
WP
Department of Urology, University Hospital Nijmegen, The Netherlands.
Robertson
A
A
Rosier
P F
PF
Neal
D E
DE
Debruyne
F M
FM
de la Rosette
J J
JJ
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000368:Aged; D006801:Humans; D053685:Laser Therapy; D008297:Male; D008872:Microwaves / Q000627:therapeutic use; D008875:Middle Aged; D011224:Prazosin / Q000031:analogs & derivatives / Q000627:therapeutic use; D011446:Prospective Studies; D011468:Prostatectomy; D011470:Prostatic Hyperplasia / Q000150:complications / Q000628:therapy*; D001748:Urinary Bladder Neck Obstruction / Q000145:classification / Q000209:etiology* / Q000503:physiopathology; D014563:Urodynamics
D000317:Adrenergic alpha-Antagonists; C041226:Terazosin; D011224:Prazosin